Newsletter
Abaloparatide for osteoporosis, cost-effectiveness of PCSK9 inhibitors, review of aortic dissection, and more

JAMA Editor’s Summary

Abaloparatide for osteoporosis, cost-effectiveness of PCSK9 inhibitors, review of aortic dissection, and more

Editor's Audio Summary by Edward Livingston, MD, Deputy Editor, JAMA, the Journal of the American Medical Association, for the
August 16, 2016

Abaloparatide for osteoporosis, cost-effectiveness of PCSK9 inhibitors, review of aortic dissection, and more

Editor’s Audio Summary by Edward Livingston, MD, Deputy Editor, JAMA, the Journal of the American Medical Association, for the August 16, 2016 issue

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
What Will Variant Sigma Look Like? with Michael T. Osterholm, Ph.D., Regents Professor, Division of Environmental Health Science; Director, Center for Infectious Disease Research and Policy (CIDRAP) University of Minnesota